Initiation of Multiple Ascending Dose Phase 1 Study of PRX002 in Patients With Parkinson's Disease

finance.yahoo.com/news/initiation-multiple-ascending-dose-phase-200602248.html

First Patient with Parkinson` s Disease Successfully Dosed in Second Phase 1 Study Trial Designed to Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity Multiple...

Global Parkinson's Disease Market 2014-2018: Key Vendors are Boehringer Ingelheim, GlaxoSmithKline, Novartis and Teva

finance.yahoo.com/news/global-parkinsons-disease-market-2014-104754060.html

Dublin -- Research and Markets (http://www.researchandmarkets.com/research/d6g555/global) has announced the addition of the "Global Parkinson' s Disease Market 2014-2018" report to...

First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development

ca.finance.yahoo.com/news/first-clinical-data-therapeutic-parkinsons-151000562.html

AFFiRiS AG announced today at a press conference in New York results of AFF008, a Phase I clinical trial of PD01A, a vaccine against Parkinson' s disease. PD01A is the first...

Beyond the tremors: Understanding the impact of Parkinson’s disease

www.australasianscience.com.au/article/issue-julyaugust-2014/beyond-tremors-understanding-impact-parkinson%E2%80%99s-disease.html

Neuroscientist and neurologist Prof Malcolm Horne discusses Parkinson’s disease, and examines new technological developments and the prospects they offer for early diagnosis and...

Penn researchers: Naltrexone may diminish impulse control disorders in Parkinson's disease patients

www.eurekalert.org/pub_releases/2014-07/uops-prn073014.php

Up to 20 percent of Parkinson' s disease patients may confront a common but largely unrecognized challenge: the occurrence of impulse control disorders (ICDs) such as compulsive...

First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development

www.prnewswire.com/news-releases/first-clinical-data-of-therapeutic-parkinsons-disease-vaccine-encourages-continued-development-269390241.html

NEW YORK and VIENNA, July 31, 2014 /PRNewswire/ -- AFFiRiS AG announced today at a press conference in New York results of AFF008, a Phase I clinical trial of PD01A, a vaccine...

Parkinson's Could Enhance Creativity

news.yahoo.com/parkinsons-could-enhance-creativity-160051798.html

People with Parkinson' s disease may have higher levels of creativity than their healthy peers, a new study finds. Many case studies show that patients with FTD develop a sudden...

Middletown Healthline Radio Show To Discuss Parkinson's

hartfordcourant.feedsportal.com/c/34278/f/623630/s/3d1713d3/sc/7/l/0L0Scourant0N0Ccommunity0Cmiddletown0Chc0Emiddletown0Ehealthline0Eparkinsons0E0A80A10E20A140A80A10H0A0H7549510Bstory0Dtrack0Frss/story01.htm

MIDDLETOWN — The August edition of the Healthline radio show will Parkinson's disease.

Biotie updates outlook on tozadenant and SYN120

finance.yahoo.com/news/biotie-updates-outlook-tozadenant-syn120-055202531.html

BIOTIE THERAPIES CORP.              STOCK EXCHANGE RELEASE     30 July 2014      at 8.50 a.m. Biotie updates outlook on tozadenant and SYN120 Tozadenant to advance into Phase 3 in ...

Global Parkinson%s Disease Market 2014-2018

ca.finance.yahoo.com/news/global-parkinson-disease-market-2014-224200044.html

LONDON, July 28, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Global Parkinson% s Disease Market 2014-2018...